Quarterly Earnings

China's EdTech giant TAL is set to report Q4 earnings. Investors are watching closely to see if its pivot to AI and smart devices is a winning strategy.

As Option Care Health preps its Q1 results, investors watch if it can seize market share from a retreating rival while navigating major biosimilar headwinds.

ADP's latest dividend declaration highlights its financial strength and commitment to shareholders, cementing its status as a reliable income-generating stock.

With stellar trial data for its cholesterol drug obicetrapib, NewAmsterdam Pharma faces investors as it navigates a competitive market and awaits key results.

As Cincinnati Financial preps its Q1 2026 results, we dive into the key metrics and industry trends that will define its performance and market reaction.

Beasley Broadcast Group reports a staggering $190M Q4 loss after a massive asset write-down, but a major debt cut and digital growth signal a fight for survival.

The Norwegian tech firm is shifting its business model with a new platform designed to tame complex, multi-vendor environments and drive recurring revenue.

With a massive $750M boost to its share buyback, Nutanix underscores its financial strength and bets on its future in hybrid multicloud and enterprise AI.

The revolving sushi chain posts strong sales and narrows losses, proving its automation and expansion strategy is paying off despite economic pressures.

Facing a shareholder revolt after a damning indictment, Supermicro launches a major probe into a $2.5B shadow trade scheme. Is it too little, too late?

With its Q1 earnings call on May 7, STARZ faces investor scrutiny on subscriber growth, content strategy, and its path to profitability post-spinoff.

With its lead cancer drug advancing and a strong balance sheet, Nurix will detail its vision for protein degradation at a key investor conference.

A new report reveals a major education gap in obesity care. Informed patients are now demanding options beyond blockbuster drugs like Wegovy and Zepbound.

As Molson Coors preps its Q1 2026 earnings call, all eyes are on its strategy to combat declining volumes and rising costs in a pivotal "reset year."

Outset Medical appoints Derick Elliott as commercial EVP, a strategic move to accelerate its Tablo dialysis system and capitalize on the hospital insourcing trend.

As Ryan Specialty preps its Q1 2026 results, investors watch to see if the firm can rebound from a tough quarter and navigate a complex insurance market.

Axe Compute names Kyle Okamoto President, a strategic hire signaling a major push to solve the AI 'distribution problem' and challenge hyperscaler dominance.

Newsweek names Bloom Energy a top trustworthy company. We explore how 25 years of reliability, investor confidence, and market demand are shaping its future.

Amidst rising costs and market volatility, Centene appoints two new Group Presidents. Is this strategic overhaul the key to future growth and profitability?

The bank's Q1 2026 earnings show improved interest margins and steady dividends, painting a picture of resilience in a complex Hawaiian economy.